Millions of patients are flocking to GLP-1 weight loss injections, but artificial intelligence has just uncovered a hidden wave of disturbing side effects sweeping through online communities.
A new study from the University of Pennsylvania, published in the journal Nature Health, used large language models to scan more than 400,000 posts from nearly 70,000 Reddit users discussing GLP-1 drugs like semaglutide and tirzepatide.
While traditional clinical trials have extensively documented gastrointestinal issues, the AI analysis revealed that patients are frequently experiencing severe fatigue, sudden temperature fluctuations, and significant reproductive changes that are not currently captured on official drug labelling.
A digital grapevine
Lyle Ungar, a professor of computer and information science who co-authored the study, explained that clinical trials often fail to identify the symptoms patients are most concerned about.
Ungar said: “Online patient communities work a lot like a neighbourhood grapevine. People who are living with these medications are swapping notes with each other in real time, sharing experiences that rarely make it into a doctor’s office visit or an official report.”
Using advanced AI models like GPT and Gemini, the researchers were able to conduct “computational social listening” at an unprecedented scale, mapping casual online complaints directly to official medical terminology.
The AI data revealed that about 44 per cent of users described experiencing at least one side effect. Surprisingly, fatigue ranked as the second most common complaint overall, despite rarely reaching the reporting thresholds during initial clinical trials.
Nearly four per cent of the total users reported severe reproductive symptoms, including intermenstrual bleeding, unusually heavy bleeding, and highly irregular cycles. Others frequently reported temperature-related complaints, such as severe chills, sudden hot flushes, and fever-like symptoms.
The biological trigger
Jena Shaw Tronieri, a senior research investigator at Penn’s Center for Weight and Eating Disorders, explained that GLP-1 drugs engage the hypothalamus — the part of the brain that helps regulate hormones. This neurological link makes it highly plausible that the medication could trigger both fluctuations in body temperature and menstrual changes.
The researchers argue that while clinical trials remain the gold standard for identifying dangerous side effects, they simply move too slowly to capture the full patient experience when a drug skyrockets in popularity.
Sharath Chandra Guntuku, the study’s senior author, said: “Clinical trials are the gold standard, but by design, they are slow. This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight.”
